Oligo Medic, Inc., a global biomaterials company, today announced the Health Canada approval and Canadian launch of the JointRep™ injectable implant for the treatment of cartilage defects in the knee joint. JointRep™ has been shown to help reduce pain and stiffness in patients who have suffered cartilage loss. With the approval of the JointRep™ device, patients in Canada who have not experienced relief of pain or stiffness from their current medical management will now have access to a new biomaterial based medical device that has been clinically shown to help alleviate the often debilitating symptoms associated with cartilage loss and degradation.
"The JointRep™ biomaterial underscores Oligo Medic's commitment to innovation and advancing products designed to improve patient satisfaction and quality of life," said Jerett A. Creed, chief executive officer at Oligo Medic Inc.. "The approval of JointRep™ represents the first step in our vision of imagining a world without metals where physicians have increased access to less invasive treatments to help their patients make decisions that best fit their lives."
JointRep™ represents a new class of treatment for the repair of cartilage defects. JointRep™ is an arthroscopically administered biomaterial (in situ forming polyglucosamine hydrogel) designed to augment a marrow stimulation procedure. When used in this manner, it has been clinically shown to reduce pain and stiffness in the knee joint by more than 90% for at least two years with a single treatment. The product is available in more than 20 countries.
About Oligo Medic Inc.
Oligo Medic is a global medical device company with a focus on the use of biomaterials and advanced therapeutics to treat some of the world's most complex diseases. Headquartered in Laval, Quebec, Oligo Medic sells in approximately 20 countries around the globe. For more information, please visit oligomedic.com
SOURCE Oligo Medic inc.